Omacetaxine mepesuccinate

Drug Profile

Omacetaxine mepesuccinate

Alternative Names: Ceflatonin®; CGX-635; CXS-635; HHT; Homoharringtonine; Homoharringtonine-ChemGenex; NCI 141633; Omapro™; Synribo

Latest Information Update: 07 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemGenex Pharmaceuticals; Stragen Pharma SA
  • Developer ChemGenex Pharmaceuticals; Roswell Park Cancer Institute; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Alkaloids; Harringtonines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin D1 inhibitors; MCL1 protein inhibitors; Protein synthesis inhibitors; Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Chronic myeloid leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies
  • Discontinued Acute promyelocytic leukaemia; Solid tumours

Most Recent Events

  • 07 Jul 2017 Discontinued - Phase-I for Solid tumours (Second-line therapy or greater) in Netherlands (SC)
  • 07 Jul 2017 Discontinued - Phase-II for Acute myeloid leukaemia (Combination therapy, In the elderly) in USA (SC)
  • 07 Jul 2017 Discontinued - Phase-II for Chronic myeloid leukaemia (Second-line therapy or greater) in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top